Howard Gurney
Westmead Hospital · 456 works · 37,424 citations · h-index 64
Top works
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
- Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
- Initial Paclitaxel Improves Outcome Compared With CMFP Combination Chemotherapy as Front-Line Therapy in Untreated Metastatic Breast Cancer
- How to calculate the dose of chemotherapy
- Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
- Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
- Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
- Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
- Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
- Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial